Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use

Page View:
On June 10, 2022, Bio-Thera Solutions, Ltd. (Bio-Thera) announced that BAT2022 for injection has obtained a clinical trial approval.  BAT2022 for injection is a bispecific neutralizing antibody independently developed by Bio-Thera, which is intended to be used for the treatment of new coronary pneumonia caused by the infection of the COVID19 and its mutants.

Shanghai Medicilon Inc. was honored to participate in the R&D project of Bio-Thera BAT202 for injection, providing a safety evaluation test that complied with the GLP specification and assisting the project successfully obtain clinical approval with compliant, efficient and high-quality services.

Medicilon provides antibody drugs discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services. As of the end of June 2023, Medicilon has successfully assisted in the clinical approval of 31 antibody drugs (8 approved by FDA and NMPA, 1 approved by NMPA and TGA, 1 approved by FDA, NMPA, and TGA) and has multiple antibody projects under development.


Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!

Development History and Market Prospects of Bispecific Antibodies

The Biological Analysis of Bispecific Atibody
About Bio-Thera
Bio-Thera is committed to developing a new generation of innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life or health.  As a leader in the research and development of next-generation antibody drugs, Bio-Thera has promoted a number of drug candidates into later-stage of clinical trials.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.
Contact us:
Relevant newsRelevant news